[go: up one dir, main page]

NO20020999L - Mesoprogestiner (progesteronreseptormodulatorer) for behandling og forhindring av godartete hormonavhengigegynekologiske sykdommer - Google Patents

Mesoprogestiner (progesteronreseptormodulatorer) for behandling og forhindring av godartete hormonavhengigegynekologiske sykdommer

Info

Publication number
NO20020999L
NO20020999L NO20020999A NO20020999A NO20020999L NO 20020999 L NO20020999 L NO 20020999L NO 20020999 A NO20020999 A NO 20020999A NO 20020999 A NO20020999 A NO 20020999A NO 20020999 L NO20020999 L NO 20020999L
Authority
NO
Norway
Prior art keywords
mesoprogestins
prevention
treatment
receptor modulators
progesterone receptor
Prior art date
Application number
NO20020999A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020999D0 (no
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of NO20020999D0 publication Critical patent/NO20020999D0/no
Publication of NO20020999L publication Critical patent/NO20020999L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20020999A 1999-08-31 2002-02-28 Mesoprogestiner (progesteronreseptormodulatorer) for behandling og forhindring av godartete hormonavhengigegynekologiske sykdommer NO20020999L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31
PCT/US2000/023770 WO2001015679A2 (en) 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Publications (2)

Publication Number Publication Date
NO20020999D0 NO20020999D0 (no) 2002-02-28
NO20020999L true NO20020999L (no) 2002-03-14

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020999A NO20020999L (no) 1999-08-31 2002-02-28 Mesoprogestiner (progesteronreseptormodulatorer) for behandling og forhindring av godartete hormonavhengigegynekologiske sykdommer

Country Status (34)

Country Link
EP (1) EP1229906B1 (sh)
JP (1) JP2003535029A (sh)
KR (3) KR100864547B1 (sh)
AR (1) AR025457A1 (sh)
AT (1) ATE375160T1 (sh)
AU (1) AU781840B2 (sh)
BG (1) BG65817B1 (sh)
BR (1) BR0014161A (sh)
CA (1) CA2382580C (sh)
CO (1) CO5200772A1 (sh)
CZ (1) CZ2002704A3 (sh)
DE (1) DE60036723T2 (sh)
DK (1) DK1229906T3 (sh)
EA (1) EA007854B1 (sh)
EE (1) EE05172B1 (sh)
ES (1) ES2295050T3 (sh)
HR (1) HRP20020267A2 (sh)
HU (1) HUP0202429A3 (sh)
IL (1) IL148416A0 (sh)
LT (1) LT5034B (sh)
LV (1) LV12941B (sh)
ME (1) MEP13808A (sh)
MX (1) MXPA02002191A (sh)
NO (1) NO20020999L (sh)
NZ (1) NZ517471A (sh)
PE (1) PE20010578A1 (sh)
PL (1) PL198790B1 (sh)
PT (1) PT1229906E (sh)
RO (1) RO122179B1 (sh)
RS (1) RS50283B (sh)
SI (1) SI20852B (sh)
SK (1) SK287192B6 (sh)
UA (1) UA78184C2 (sh)
WO (1) WO2001015679A2 (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
EP1525215B1 (de) * 2002-08-02 2006-09-06 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
KR20120064067A (ko) * 2009-06-17 2012-06-18 고꾸리쯔다이가꾸호오진 구마모또 다이가꾸 월경곤란증의 예방 및/또는 치료약
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
CN114728013A (zh) * 2019-09-23 2022-07-08 斯坦福大学托管董事会 延长妊娠以及月经或妊娠的并发症的治疗方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
NZ300739A (en) * 1994-12-22 2000-05-26 Ligand Pharm Inc Steroid receptor modulator compounds
US5688810A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP0806952B1 (de) 1995-02-02 2003-04-02 Schering Aktiengesellschaft Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
EP0900234B1 (en) * 1996-05-01 2000-07-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (en) * 1999-01-14 2001-10-17 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
AU781840B2 (en) 2005-06-16
NZ517471A (en) 2004-02-27
BG65817B1 (bg) 2010-01-29
BG106442A (bg) 2002-09-30
LT2002031A (en) 2003-02-25
WO2001015679A3 (en) 2001-11-22
DK1229906T3 (da) 2008-02-11
EE05172B1 (et) 2009-06-15
EP1229906A2 (en) 2002-08-14
CA2382580C (en) 2009-05-19
DE60036723T2 (de) 2008-07-17
KR100864547B1 (ko) 2008-10-20
PE20010578A1 (es) 2001-06-04
AU6946600A (en) 2001-03-26
KR20070058023A (ko) 2007-06-07
EE200200104A (et) 2003-04-15
JP2003535029A (ja) 2003-11-25
YU14002A (sh) 2006-01-16
WO2001015679A2 (en) 2001-03-08
UA78184C2 (en) 2007-03-15
MEP13808A (en) 2010-06-10
LT5034B (lt) 2003-07-25
HRP20020267A2 (en) 2004-04-30
IL148416A0 (en) 2002-09-12
MXPA02002191A (es) 2002-09-30
CA2382580A1 (en) 2001-03-08
CZ2002704A3 (cs) 2003-02-12
ATE375160T1 (de) 2007-10-15
KR20080066095A (ko) 2008-07-15
DE60036723D1 (de) 2007-11-22
EA200200282A1 (ru) 2002-10-31
AR025457A1 (es) 2002-11-27
LV12941B (en) 2003-06-20
KR100755109B1 (ko) 2007-09-04
BR0014161A (pt) 2002-05-21
SI20852B (sl) 2009-06-30
PL198790B1 (pl) 2008-07-31
EP1229906B1 (en) 2007-10-10
CO5200772A1 (es) 2002-09-27
KR20020027616A (ko) 2002-04-13
HUP0202429A2 (en) 2002-10-28
RS50283B (sr) 2009-09-08
EA007854B1 (ru) 2007-02-27
SK287192B6 (sk) 2010-02-08
RO122179B1 (ro) 2009-02-27
HUP0202429A3 (en) 2004-04-28
SI20852A (sl) 2002-10-31
SK2992002A3 (en) 2002-07-02
PT1229906E (pt) 2008-01-18
ES2295050T3 (es) 2008-04-16
PL353930A1 (en) 2003-12-15
NO20020999D0 (no) 2002-02-28

Similar Documents

Publication Publication Date Title
NO20020912D0 (no) Bicykliske androgen- og progesteronreseptorer- modulatorforbindelser og fremgangsmåter
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
ATE293971T1 (de) Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten
NO20024478L (no) Hormonerstatningsterapi ved anvendelse av kombinasjon av konjugerte östrogener og medroksyprogesteronacetat
NO20022925L (no) EP4 reseptor selektive agonister for behandling av osteoporose
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
IS1886B (is) Stjórnuð losun stera úr sykruhúðum
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
IL147012A0 (en) Indole derivatives and their use for the treatment of osteoporosis amongst other applications
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20005885D0 (no) Kombinasjonsterapi for behandling av refraktær depresjon
NO20020999L (no) Mesoprogestiner (progesteronreseptormodulatorer) for behandling og forhindring av godartete hormonavhengigegynekologiske sykdommer
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
NO20003229D0 (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske legemidler for behandling av proliferaktive sykdommer
NO20014049L (no) Kontrollert frigjörings-formulering for behandling av COPD
NO983465D0 (no) Farmas°ytisk kombinasjonspreparater inneholdende LHRH-analoger og anti°strogener for behandling av gynekologiske forstyrrelser
NO983512D0 (no) Midler for behandling og forhindring av AIDS
NO20013651D0 (no) Anvendelse av fosfororganiske forbindelser for profylaktisk og terapeutisk behandling av infeksjoner
NO20023841D0 (no) Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemethos menn
DE60032655D1 (de) Einrichtung zur Chirurgie der Hornhaut
AU2001279764A1 (en) Device for heat treatment of the vaginal or colonic region

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application